Europe

Recipharm appoints Lennernäs to operating board

Wednesday, February 6, 2013 12:38 PM

Recipharm, a contract development and manufacturing organization based in Sweden, has appointed Dr. Hans Lennernäs to the operating board of Recipharm Pharmaceutical Development.

More... »

British public wants to crowdfund innovative companies

Tuesday, February 5, 2013 08:00 AM

The British public wants the opportunity to crowdfund innovative British companies. That is the message from a YouGov survey commissioned by the BioIndustry Association (BIA) which shows that nearly nine out of 10 U.K. adults who expressed a preference agree that the general public should be provided with the opportunity to invest modest sums of money, if they wish to, into funds that will be targeted towards innovative companies.

More... »

Patheon increases investment in Milton Park, U.K. facility

Monday, February 4, 2013 12:27 PM

Patheon, a provider of contract development and commercial manufacturing services, has announced plans for additional investment in its Milton Park facility. Located in Oxfordshire, U.K., Milton Park is a dedicated pharmaceutical development services facility focused on early development projects.

More... »

Domain grants Prexton exclusive license and development of mGluR4 PAMs for Parkinson’s

Friday, January 25, 2013 11:01 AM

Domain Therapeutics, a French biopharmaceutical company, has granted Switzerland–based Prexton Therapeutics an exclusive option to license and develop metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson’s disease.

More... »

Verum.de to provide clinical research services for oncology center in Romania

Wednesday, January 23, 2013 02:38 PM

Verum.de, a Germany-based full-clinical service CRO, has entered into an agreement with the Center for Oncologic Diagnosis and Treatment (Oncocard) in Romania to be its preferred provider of clinical trial services.

More... »

Tresiba and Ryzodeg receive marketing authorizations in Europe

Wednesday, January 23, 2013 11:54 AM

The European Commission has granted marketing authorizations for Novo Nordisk’s Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) for the treatment of diabetes in adults.

More... »

Almac completes Knowledge Transfer Partnership with Queens University

Wednesday, January 23, 2013 10:28 AM

Global service provider Almac has successfully completed the Knowledge Transfer Partnership (KTP) with Queens University Belfast, to develop, improve and embed bioprocesses in order to facilitate the delivery of novel products for its biocatalysis business. 

More... »

U.K. clinical trials database first major output for Cell Therapy Catapult

Friday, January 18, 2013 01:52 PM

The Cell Therapy Catapult, focused on the development of the U.K. cell therapy industry to increase the nation's health and wealth, has published its database of ongoing clinical trials in this area in the U.K.

More... »

Covance launches five-year collaboration on early clinical research

Friday, January 18, 2013 01:23 PM

Global CRO Covance and the Royal Liverpool and Broadgreen University Hospitals NHS Trust have entered into a five-year exclusive agreement to work together in conducting early clinical trials at the Royal Liverpool University Hospital on behalf of biotechnology and pharmaceutical companies.

More... »

Almac doubles drug development capacity with a new non-GMP facility

Monday, January 14, 2013 10:11 AM

Global service provider Almac has expanded its drug product pharmaceutical development services with the creation of a new non-GMP formulation development facility and two new analytical laboratories at its U.K. headquarters in Craigavon.

More... »